Pneumococcal vaccination of older adults: Conjugate or polysaccharide?

Human Vaccines and Immunotherapeutics

Volumn 10, Issue 1, 2014, Pages 45-46

  Hollingsworth, Rosalind ^a   Isturiz, Raul ^a  

^a PFIZER INC   (United States)

Author keywords

Adults; Bacterial; Clinical; Conjugate; Pneumococcal; Polysaccharide vaccine; Protein conjugate vaccine; Vaccination; Vaccinology

Indexed keywords

PNEUMOCOCCUS VACCINE; PPSV 23; UNCLASSIFIED DRUG;

ANTIBODY RESPONSE; COST EFFECTIVENESS ANALYSIS; DRUG APPROVAL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; HUMAN; IMMUNE RESPONSE; LETTER; REVACCINATION; SEROTYPE; STREPTOCOCCUS PNEUMONIA; UNITED STATES; VACCINATION;

EID: 84896711597     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.26330     Document Type: Letter

References (18)

1. Jackson LA, Neuzil KM. Pneumococcal polysaccharide vaccine. In: Plotkin SA, Orenstein WA, eds. Vaccines 5th Edition. Philadelphia, PA: Saunders, Elsevier; 2008:569-604.
2. Huss A, Scott P, Stuck AE, Trotter C, Egger M. Efficacy of pneumococcal vaccination in adults: a meta-analysis. CMAJ 2009; 180:48-58; PMID:19124790; http://dx.doi.org/10.1503/cmaj.080734
3. Moberley S, Holden J, Tatham DP, Andrews RM. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev 2013; 1:CD000422; PMID:23440780
4. Hansen J, Black S, Shinefield H, Cherian T, Benson J, Fireman B, Lewis E, Ray P, Lee J. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than 5 years of age for prevention of pneumonia: updated analysis using World Health Organization standardized interpretation of chest radiographs. Pediatr Infect Dis J 2006; 25:779-81; PMID:16940833; http://dx.doi.org/10.1097/01.inf.0000232706.35674.2f
5. Cutts FT, Zaman SMA, Enwere G, Jaffar S, Levine OS, Okoko JB, Oluwalana C, Vaughan A, Obaro SK, Leach A, et al.; Gambian Pneumococcal Vaccine Trial Group. Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial. Lancet 2005; 365:1139-46; PMID:15794968; http://dx.doi.org/10.1016/S0140-6736(05)71876-6
6. Griffin MR, Zhu Y, Moore MR, Whitney CG, Grijalva CG. U.S. hospitalizations for pneumonia after a decade of pneumococcal vaccination. N Engl J Med 2013; 369:155-63; PMID:23841730; http://dx.doi.org/10.1056/ NEJMoa1209165
7. Fedson DS, Guppy MJ. Pneumococcal vaccination of older adults: conjugate or polysaccharide? Hum Vaccin Immunother 2013; 9: (Forthcoming); PMID:23732892; http://dx.doi.org/10.4161/hv.24692
8. Jackson LA, Gurtman A, van Cleeff M, Jansen KU, Jayawardene D, Devlin C, Scott DA, Emini EA, Gruber WC, Schmoele-Thoma B. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults. Vaccine 2013; 31:3577-84; PMID:23688526; http://dx.doi.org/10.1016/j.vaccine.2013.04.085
9. Jackson LA, Gurtman A, Rice K, Pauksens K, Greenberg RN, Jones TR, Scott DA, Emini EA, Gruber WC, Schmoele-Thoma B. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. Vaccine 2013; 31:3585-93; PMID:23688527; http://dx.doi.org/10.1016/j.vaccine. 2013.05.010
10. Jackson LA, Gurtman A, van Cleeff M, Frenck RW, Treanor J, Jansen KU, Scott DA, Emini EA, Gruber WC, Schmoele-Thoma B. Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older. Vaccine 2013; 31:3594-602; PMID:23688525; http://dx.doi.org/10.1016/j.vaccine.2013.04.084
11. Grijalva CG, Nuorti JP, Arbogast PG, Martin SW, Edwards KM, Griffin MR. Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet 2007; 369:1179-86; PMID:17416262; http://dx.doi.org/10.1016/S0140-6736(07)60564-9
12. Nelson JC, Jackson M, Yu O, Whitney CG, Bounds L, Bittner R, Zavitkovsky A, Jackson LA. Impact of the introduction of pneumococcal conjugate vaccine on rates of community acquired pneumonia in children and adults. Vaccine 2008; 26:4947-54; PMID:18662735; http://dx.doi.org/10.1016/j.vaccine.2008.07.016
13. Simonsen L, Taylor RJ, Young-Xu Y, Haber M, May L, Klugman KP. Impact of pneumococcal conjugate vaccination of infants on pneumonia and influenza hospitalization and mortality in all age groups in the United States. MBio 2011; 2:e00309-10; PMID:21264063; http://dx.doi.org/10.1128/mBio.00309-10
14. Sherwin RL, Gray S, Alexander N, et al. Distribution of PCV13-serotype Streptococcus pneumoniae in Adults Aged ? 50 Years Presenting to Select US Hospitals with Radiographically-Confirmed Community-Onset Pneumonia. Presented at the inaugural IDWeek. San Diego, CA. October 17-21 2012.
15. Pride MW, Huijts SM, Wu K, Souza V, Passador S, Tinder C, Song E, Elfassy A, McNeil L, Menton R, et al. Validation of an immunodiagnostic assay for detection of 13 Streptococcus pneumoniae serotype-specific polysaccharides in human urine. Clin Vaccine Immunol 2012; 19:1131-41; PMID:22675155; http://dx.doi.org/10.1128/CVI.00064-12
16. Smith KJ, Wateska AR, Nowalk MP, Raymund M, Lee BY, Zimmerman RK. Modeling of cost effectiveness of pneumococcal conjugate vaccination strategies in U.S. older adults. Am J Prev Med 2013; 44:373-81; PMID:23498103; http://dx.doi.org/10.1016/j.amepre.2012.11.035
17. Weycker D, Sato R, Strutton D, Edelsberg J, Atwood M, Jackson LA. Public health and economic impact of 13-valent pneumococcal conjugate vaccine in US adults aged ?50 years. Vaccine 2012; 30:5437-44; PMID:22728289; http://dx.doi.org/10.1016/j.vaccine.2012.05.076
18. Yang HK, Chen J, O'Brien M, et al. Costeffectiveness of Pneumococcal Vaccines for Adults in the United States. Presented at ISPOR 18th Annual International Meeting, New Orleans, LA. May 18-22 2013.